CSPC Pharmaceutical Group Limited CSPCY
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -4.26% | -- | -13.57% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -4.26% | -- | -13.57% | -- |
| Cost of Revenue | -- | 5.26% | -- | -0.76% | -- |
| Gross Profit | -- | -8.66% | -- | -18.91% | -- |
| SG&A Expenses | -- | -11.06% | -- | -23.20% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 0.95% | -- | -8.04% | -- |
| Operating Income | -- | -28.16% | -- | -34.26% | -- |
| Income Before Tax | -- | -20.67% | -- | -21.49% | -- |
| Income Tax Expenses | -- | -20.11% | -- | -18.03% | -- |
| Earnings from Continuing Operations | -- | -20.82% | -- | -22.35% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 13.81% | -- | 85.26% | -- |
| Net Income | -- | -20.84% | -- | -21.45% | -- |
| EBIT | -- | -28.16% | -- | -34.26% | -- |
| EBITDA | -- | -21.15% | -- | -27.76% | -- |
| EPS Basic | -- | -18.91% | -- | -18.84% | -- |
| Normalized Basic EPS | -- | -27.23% | -- | -17.98% | -- |
| EPS Diluted | -- | -18.91% | -- | -18.84% | -- |
| Normalized Diluted EPS | -- | -27.23% | -- | -17.98% | -- |
| Average Basic Shares Outstanding | -- | -1.93% | -- | -2.93% | -- |
| Average Diluted Shares Outstanding | -- | -1.93% | -- | -2.93% | -- |
| Dividend Per Share | -- | 9.31% | -- | -19.21% | -- |
| Payout Ratio | -- | -- | -- | -- | -- |